Certolizumab pegol, sold under the brand name Cimzia, is a biopharmaceutical medication for the treatment of Crohn's disease,[2][3] rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.[4][5][6]
Monoclonal antibody | |
---|---|
Type | Fab' fragment |
Source | Humanized (from mouse) |
Target | TNF alpha |
Clinical data | |
Trade names | Cimzia |
Other names | CDP870 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a608041 |
License data | |
Pregnancy category |
|
Routes of administration | Subcutaneous |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | about 11 days |
Excretion | Kidney (PEG only) |
Identifiers | |
CAS Number |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C2115H3252N556O673S16 |
Molar mass | 47749.46 g·mol−1 |
(what is this?) (verify) |
It is on the World Health Organization's List of Essential Medicines.[7]
Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.[13]